A KLK2×CD3 T-cell–redirecting bispecific antibody that binds KLK2 on prostate tumor cells and CD3 on T cells to trigger TCR-mediated cytotoxicity.
Bispecific antibody that binds KLK2 on prostate tumor cells and CD3 on T cells, redirecting T cells to form an immune synapse and induce TCR-mediated activation and cytotoxic lysis of KLK2-expressing cancer cells.
NO
INDIRECT
Binding to CD3 activates T cells and redirects them to lyse KLK2-positive tumor cells via TCR-mediated perforin/granzyme cytotoxicity; CD3+ T cells are not killed.
A PSMA×CD28 costimulatory bispecific antibody that binds PSMA on tumor cells and CD28 on T cells to deliver costimulatory signals and enhance T-cell activation in PSMA-positive settings.
PSMA×CD28 costimulatory bispecific antibody that binds PSMA on tumor cells and CD28 on T cells to provide CD28-mediated costimulation, enhancing T-cell activation and redirecting cytotoxicity toward PSMA-positive tumor cells.
YES
DIRECT
The bispecific links CD28 on T cells to PSMA on tumor cells, providing CD28 costimulation that activates T cells and redirects them to kill PSMA+ cells via CTL-mediated cytotoxicity (e.g., perforin/granzyme).
Polyclonal antibody preparation that depletes T lymphocytes for induction immunosuppression.
Polyclonal anti–T-lymphocyte IgG that binds multiple T-cell surface antigens and depletes T cells via complement-dependent cytotoxicity and Fc-mediated ADCC, with additional T-cell apoptosis and functional inhibition, producing potent immunosuppression.
YES
DIRECT
ATG binds CD2 on T cells, leading to complement-dependent lysis and Fc receptor–mediated ADCC, with additional induction of apoptosis.
A PSMA×CD28 costimulatory bispecific antibody that binds PSMA on tumor cells and CD28 on T cells to deliver costimulatory signals and enhance T-cell activation in PSMA-positive settings.
PSMA×CD28 costimulatory bispecific antibody that binds PSMA on tumor cells and CD28 on T cells to provide CD28-mediated costimulation, enhancing T-cell activation and redirecting cytotoxicity toward PSMA-positive tumor cells.
NO
INDIRECT
The bispecific binds CD28 on T cells to provide costimulation while engaging PSMA on tumor cells; activated T cells kill PSMA-positive tumor cells, not CD28-expressing cells.
Autologous, gene-modified TCR T-cell therapy engineered to express an HLA-A*02:01–restricted TCR recognizing HPV16/52 antigens; mediates antigen-specific cytotoxicity and cytokine release against HPV-positive tumor cells; administered after lymphodepletion.
Autologous T cells genetically engineered to express an HLA-A*02:01–restricted TCR that recognizes HPV16/52-derived peptides on tumor cells; antigen/MHC engagement activates the T cells to release cytotoxic granules and cytokines, mediating targeted killing of HPV-positive tumor cells. Administered after lymphodepletion to promote expansion and persistence.
YES
DIRECT
Engineered TCR T cells recognize the HPV16 peptide-HLA-A*02:01 complex on target cells and induce cytolysis via perforin/granzyme release (with additional Fas-FasL/cytokine-mediated apoptosis).